NuVasive

NuVasive, Inc. engages in the development, manufacture, sale, and provision of procedural solutions for spine surgery. It offers a comprehensive portfolio of procedurally integrated spine surgery solutions, including surgical access instruments, spinal implants, fixation systems, biologics, and enabling technologies, as well as systems and services for intraoperative neuromonitoring. The company was founded by Alexis V. Lukianov on July 21, 1997 and is headquartered in San Diego, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NuVasive is a medical device company that creates minimally invasive surgical products and procedurally integrated spine solutions. Its minimally invasive, procedurally integrated surgical solutions are intended to produce repeatable and clinically proven results.

NuVasive looks to be on better footing with new management, but it will take time for late investments in areas like robotics to really show up in the results.

NuVasive Is On A Better Path, But Remains A 'Show Me' Story

Introduction of multiple products within the Spinal Hardware, balanced revenue growth across key operating segments and robust international sales perk up NuVasive's (NUVA) share price.

NuVasive Grows on Strong Product Adoption Amid Pricing Woe

The launch of Modulus TLIF-O is expected to boost the AMS portfolio of NuVasive (NUVA).

NuVasive Launches Titanium Spine Implant Modulus TLIF-O

NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock?

Why Is NuVasive (NUVA) Down 3.9% Since Last Earnings Report?

Investor confidence in the stock is high on NuVasive's (NUVA) sturdy spine business.

Here's Why You Should Retain NuVasive (NUVA) Stock for Now

Varex Imaging

VREX vs. NUVA: Which Stock Is the Better Value Option?

NuVasive's (NUVA) solid international sales in Q1 boost investor confidence in the stock.

NuVasive (NUVA) Q1 Earnings Top Estimates, Margins Strong

NuVasive, Inc. (NUVA) CEO Chris Barry on Q1 2019 Results - Earnings Call Transcript

The spinal-surgery specialist gave investors solid performance.

NuVasive Straightens Up to Start 2019

NuVasive (NUVA) delivered earnings and revenue surprises of 29.27% and 2.21%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

NuVasive (NUVA) Q1 Earnings and Revenues Top Estimates

The analyst consensus estimate would represent a 5.13 percent increase in the company's earnings

A Preview Of NuVasive's Q1 Earnings

NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

NuVasive (NUVA) Down 1% Since Last Earnings Report: Can It Rebound?

News for NuVasive Stock (NUVA)